Senators introduce Plan B awareness bill
This article was originally published in The Tan Sheet
Sens. Hillary Clinton, D-N.Y. and Patty Murray, D-Wash., introduced legislation Sept. 27 to raise awareness about the availability of Plan B emergency contraception, which FDA approved for OTC use last year for individuals ages 18 and over (1"The Tan Sheet" Aug. 28, 2006, p. 3). Rep. Louise Slaughter, D-N.Y. introduced companion legislation, H.R. 3372, in August. The proposed program would direct the Department of Health and Human Services to establish a public education program through the Centers for Disease Control and Prevention designed to provide information to the public about emergency contraception. According to statistics cited by the lawmakers, one-third of U.S. women of reproductive age are unaware of Plan B's availability, and implementing an educational program will help reduce unintended pregnancies and decrease the number of abortions...
You may also be interested in...
Sen. Patty Murray and Rep. Louise Slaughter introduce the Emergency Contraception Education Act of 2010, authorizing a public education campaign through the Centers for Disease Control and Prevention to increase EC awareness among women and health care providers. "We must educate women about their options so they can make well-informed choices about their reproductive health," said Slaughter, D-N.Y., adding studies show one-third of women are unaware of EC drugs, such as the nonprescription levonorgestrel products Plan B One-Step and Next Choice. Murray, D-Wash., and Slaughter introduced 1S. 3504 and H.R. 5561 June 17, and have offered similar legislation in previous sessions of Congress (2"The Tan Sheet" Oct. 1, 2007, In Brief)
FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.